Amneal (AMRX) Co‑CEO Chirag K. Patel Receives 6.38M Shares

What Happened
Chirag K. Patel, President & Co‑CEO and a director of Amneal Pharmaceuticals (AMRX), was allocated 6,381,734 shares of Amneal Class A common stock on August 10, 2026. The Form 4 lists the transaction as an award/other acquisition (code A); no per‑share price or total dollar value for Patel’s shares is stated in the filing. The shares were issued in connection with Amneal’s acquisition of Kashiv BioSciences, where Amneal paid aggregate consideration of $375,000,000 in cash plus 28,942,098 shares of Amneal Class A common stock to the sellers; limited liability companies managed by Patel received the 6,381,734 shares as part of that transaction.

Key Details

• Transaction date: August 10, 2026 (reported on Form 4 filed August 12, 2026).
• Transaction type/code: Award/other acquisition (A).
• Shares acquired: 6,381,734 shares of Class A common stock.
• Price/value: Not specified for these shares in the Form 4; overall acquisition consideration included $375M cash + 28,942,098 AMRX shares.
• Shares owned after transaction: Not stated in the provided filing excerpt.
• Footnote: Allocation arose from a Membership Interest Purchase Agreement for Amneal’s acquisition of Kashiv (see F1).
• Timeliness: Filing date (Aug 12) is within the typical two‑business‑day Form 4 window for an Aug 10 transaction; filing appears timely.

Context
This was an issuance tied to a corporate acquisition, not an open‑market purchase or sale by the insider. Such acquisition‑related allocations reflect deal consideration and do not by themselves indicate personal buying or selling intent; they increase the insider’s equity stake as part of the transaction.